Table 1.

Patients with breast cancer metastases to the brain responding to hormonal therapy

Author	Age at primary diagnosis, years	Time to brain metastases, years	Tumor sites other than the brain	Cranial XRT	Endocrine therapy	Size of lesions, cm	Number of lesions	Response in brain	Other sites	Follow-up interval, months	Duration of response, months	Duration of survival, months
Carey et al, 19816	46	5	No	Prior	TAM	–	–	CR	PR	–	14	–
Hansen et al, 19868	38	30	Soft tissue	No	TAM	1–2	Multiple	PR	CR	9	27+	–
van der Gaast, 199114	35	14	Soft tissue	Prior	Megace	2.2	Single	CR	PR	1.5	9	–
Colomer et al, 19887	56	0	Breast, bone	No	TAM	2–3	Multiple	CR	PR	3.5	34	38+
Pors et al, 199110	40	28	Breast	No	TAM	–	Multiple	PR	CR	–	58	82+
Stewart et al, 199513	40	12	No	Prior	Megace	–	Single	PR		4	12	84
van Rijswijk et al, 199712	53	3	Soft tissue	No	TAM	Large	Multiple	CR	CR	6	6	–
Madhup et al, 20069	43	3	Bone, breast, soft tissue	No	Letrozole	–	Single	PR	PR/CR	21	21	–
Current case 1	38	3.6	Bone, breast, lung	No	Medroxyprogesterone	0.3–0.8	Multiple	CR	PR	10	10	–
Current case 2	37	1.4	Bone, lung, soft tissue	No	Fulvestrant	0.7	Single	PR	SD	1	1	–

Abbreviations: CR, complete response; PR, partial response; TAM, tamoxifen; SD, standard deviation; XRT, radiotherapy.